Spero Therapeutics
98 articles with Spero Therapeutics
-
Everest Medicines Announces Amended Agreement with Spero Therapeutics
1/18/2021
Spero will assign relevant SPR206 patents to Everest Medicines in Greater China, South Korea and certain Southeast Asian countries
-
Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer
12/17/2020
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment of Satyavrat “Sath” Shukla, CFA, as Chief Financial Officer, effective as of January 4, 2021
-
Spero Therapeutics Added to the NASDAQ Biotechnology Index
12/16/2020
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020. The NBI is designed t
-
Spero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease
12/10/2020
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections, today announced that it has initiated dosing in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) in its dose-ranging Phase 2a clinical trial of SPR720,
-
Spero Therapeutics Announces Appointment of Tamara Joseph as Chief Legal Officer
12/2/2020
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment of Tamara Joseph, J.D., L.L.M., as Chief Legal Officer, effective as of today.
-
Spero Therapeutics to Present at the Evercore ISI HealthCONx Conference on December 3, 2020
11/30/2020
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat at the 3 rd Annual Evercore ISI HealthCONx Con
-
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 30, 2020
11/30/2020
Spero Therapeutics, Inc. announced that on November 30, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 76,200 shares of its common stock to ten new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan.
-
Spero Therapeutics Announces Third Quarter 2020 Operating Results and Provides Business Update
11/5/2020
Achieved key clinical milestones with positive ADAPT-PO Phase 3 data and SPR720 IND acceptance
-
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 03, 2020
11/3/2020
Spero Therapeutics, Inc. announced that on October 30, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 30,000 shares of its common stock to three new employees under the Spero Therapeutics, Inc.
-
Spero Therapeutics to Provide Business Update and Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
10/29/2020
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on November 5, 2020 at 4:30 p.m
-
Spero Therapeutics to Present Data for All Pipeline Programs at IDWeek 202015 data presentations cover each of Spero’s three pipeline programs and include a late breaker oral presentation on the Phase 3 ADAPT-PO clinical trial
10/16/2020
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will have 15 data presentations at the Infectious Disease Society of America (IDSA) IDWeek™ 2020 taking place virtually from October 21 - 25, 2020. Presentations wi
-
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 30, 2020
9/30/2020
Spero Therapeutics, Inc. announced that on September 30, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,000 shares of its common stock to four new employees under the Spero Therapeutics, Inc.
-
Spero Therapeutics Hosting Key Opinion Leader Call on Oral Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections
9/24/2020
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced it will host a key opinion leader (KOL) call on oral tebipenem HBr for the treatment of complicated urinary tract infections on Wednesday, September 30, 2020
-
Spero Therapeutics to Present at Investor Conferences in September
9/15/2020
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will provide a corporate update at the following investor conferences in September
-
Spero Therapeutics Announces Pricing of Securities Offering - Sep 11, 2020
9/11/2020
Spero Therapeutics, Inc. announced the pricing of its previously announced underwritten public offering of 4,785,000 shares of its common stock and 3,215,000 shares of its non-voting Series D Convertible Preferred Stock.
-
It was a busy week for biopharma, biotech and medical device initial public offerings (IPOs). Here’s a look.
-
Spero Therapeutics Announces Proposed Public Offering
9/9/2020
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multidrug-resistant (MDR) bacterial infections and rare diseases, today announced that it has commenced an underwritten public offering of 8,000,000 shares of common stock in the aggregate, consisting of an offering of shares of common stock (the “
-
Spero Therapeutics Announces Positive Topline Results from its Phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis
9/8/2020
Pivotal Phase 3 clinical trial of oral tebipenem HBr met primary endpoint, demonstrating statistical non-inferiority versus intravenous ertapenem in patients with complicated urinary tract infection and acute pyelonephritis
-
Spero Therapeutics Announces FDA Acceptance of IND Application for SPR720
8/31/2020
Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections, today announced the acceptance by the U.S. Food and Drug Administration (FDA) of Spero’s Investigational New Drug application (IND) for SPR720,
-
Spero Therapeutics Announces Second Quarter 2020 Operating Results and Provides Business Update
8/6/2020
Top-line data for Phase 3 ADAPT-PO trial evaluating oral tebipenem HBr in complicated urinary tract infection expected in 3Q20